Výsledky vyhledávání - "Mj, Benvenga"

Schedule-controlled behavioral effects of the selective 2-amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic acid antagonist LY293558 in pigeons

Autor: Mj, Benvenga, Paul Ornstein, Jd, Leander

Publikováno v: Europe PubMed Central

Behavioral effects of the selective 2-amino-3-(5-methyl-3-hydroxyisoxazol-4- yl)propanoic acid (AMPA) antagonist LY293558, along with its racemate (LY215490) and opposing enantiomer (LY293559) were evaluated in pigeons. When responding was maintained

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::3213462b47b90e2e88f5b87590b327f8
https://pubmed.ncbi.nlm.nih.gov/7562545

Zobrazit plný text záznamu

Akademický článek

Metabotropic Glutamate 2 Receptors Play a Key Role in Modulating Head Twitches Induced by a Serotonergic Hallucinogen in Mice.

Autor: Benvenga MJ; Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, United States.; Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, United States., Chaney SF; Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, United States., Baez M; Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, United States., Britton TC; Discovery Chemistry Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, United States., Hornback WJ; Discovery Chemistry Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, United States., Monn JA; Discovery Chemistry Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, United States., Marek GJ; Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, United States.

Publikováno v: Frontiers in pharmacology [Front Pharmacol] 2018 Mar 15; Vol. 9, pp. 208. Date of Electronic Publication: 2018 Mar 15 (Print Publication: 2018).

Zobrazit plný text záznamu

Akademický článek

Preclinical findings predicting efficacy and side-effect profile of LY2940094, an antagonist of nociceptin receptors.

Autor: Witkin JM; Lilly Research Laboratories Eli Lilly and Company Indianapolis Indiana., Rorick-Kehn LM; Lilly Research Laboratories Eli Lilly and Company Indianapolis Indiana., Benvenga MJ; Lilly Research Laboratories Eli Lilly and Company Indianapolis Indiana., Adams BL; Lilly Research Laboratories Eli Lilly and Company Indianapolis Indiana., Gleason SD; Lilly Research Laboratories Eli Lilly and Company Indianapolis Indiana., Knitowski KM; Lilly Research Laboratories Eli Lilly and Company Indianapolis Indiana., Li X; Lilly Research Laboratories Eli Lilly and Company Indianapolis Indiana., Chaney S; Lilly Research Laboratories Eli Lilly and Company Indianapolis Indiana., Falcone JF; Lilly Research Laboratories Eli Lilly and Company Indianapolis Indiana., Smith JW; Lilly Research Laboratories Eli Lilly and Company Windlesham Surrey United Kingdom., Foss J; Lilly Research Laboratories Eli Lilly and Company Windlesham Surrey United Kingdom., Lloyd K; Lilly Research Laboratories Eli Lilly and Company Windlesham Surrey United Kingdom., Catlow JT; Lilly Research Laboratories Eli Lilly and Company Indianapolis Indiana., McKinzie DL; Lilly Research Laboratories Eli Lilly and Company Indianapolis Indiana., Svensson KA; Lilly Research Laboratories Eli Lilly and Company Indianapolis Indiana., Barth VN; Lilly Research Laboratories Eli Lilly and Company Indianapolis Indiana., Toledo MA; Lilly Research Laboratories Eli Lilly and Company Indianapolis Indiana; Lilly Research Laboratories Eli Lilly and Company Alcobendas Madrid Spain., Diaz N; Lilly Research Laboratories Eli Lilly and Company Alcobendas Madrid Spain., Lafuente C; Lilly Research Laboratories Eli Lilly and Company Alcobendas Madrid Spain., Jiménez A; Lilly Research Laboratories Eli Lilly and Company Alcobendas Madrid Spain., Benito A; Lilly Research Laboratories Eli Lilly and Company Alcobendas Madrid Spain., Pedregal C; Lilly Research Laboratories Eli Lilly and Company Alcobendas Madrid Spain., Martínez-Grau MA; Lilly Research Laboratories Eli Lilly and Company Alcobendas Madrid Spain., Post A; Lilly Research Laboratories Eli Lilly and Company Windlesham Surrey United Kingdom., Ansonoff MA; Lilly Research Laboratories Eli Lilly and Company Rutgers-Robert Wood Johnson Medical School New Brunswick New Jersey., Pintar JE; Lilly Research Laboratories Eli Lilly and Company Rutgers-Robert Wood Johnson Medical School New Brunswick New Jersey., Statnick MA; Lilly Research Laboratories Eli Lilly and Company Indianapolis Indiana.

Publikováno v: Pharmacology research & perspectives [Pharmacol Res Perspect] 2016 Nov 07; Vol. 4 (6), pp. e00275. Date of Electronic Publication: 2016 Nov 07 (Print Publication: 2016).

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

LSN2424100: a novel, potent orexin-2 receptor antagonist with selectivity over orexin-1 receptors and activity in an animal model predictive of antidepressant-like efficacy.

Autor: Fitch TE; Lilly Research Laboratories, Department of Neuroscience, Eli Lilly and Company Indianapolis, IN, USA., Benvenga MJ; Lilly Research Laboratories, Department of Neuroscience, Eli Lilly and Company Indianapolis, IN, USA., Jesudason CD; Lilly Research Laboratories, Department of Neuroscience, Eli Lilly and Company Indianapolis, IN, USA., Zink C; Lilly Research Laboratories, Department of Neuroscience, Eli Lilly and Company Indianapolis, IN, USA., Vandergriff AB; Lilly Research Laboratories, Department of Neuroscience, Eli Lilly and Company Indianapolis, IN, USA., Menezes MM; Lilly Research Laboratories, Department of Neuroscience, Eli Lilly and Company Indianapolis, IN, USA., Schober DA; Lilly Research Laboratories, Department of Neuroscience, Eli Lilly and Company Indianapolis, IN, USA., Rorick-Kehn LM; Lilly Research Laboratories, Department of Neuroscience, Eli Lilly and Company Indianapolis, IN, USA.

Publikováno v: Frontiers in neuroscience [Front Neurosci] 2014 Jan 28; Vol. 8, pp. 5. Date of Electronic Publication: 2014 Jan 28 (Print Publication: 2014).

Zobrazit plný text záznamu

Akademický článek

The mGlu2/3 Receptor Agonists LY354740 and LY379268 Differentially Regulate Restraint-Stress-Induced Expression of c-Fos in Rat Cerebral Cortex.

Autor: Menezes MM; Neuroscience Discovery, Eli Lilly & Company, Indianapolis, IN 46285, USA., Santini MA; Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark., Benvenga MJ; Neuroscience Discovery, Eli Lilly & Company, Indianapolis, IN 46285, USA., Marek GJ; Neuroscience Discovery, Eli Lilly & Company, Indianapolis, IN 46285, USA ; Abbott Laboratories, Global Pharmaceutical Research and Development, Neuroscience Clinical Development, Abbott Park, IL 60064-6075, USA., Merchant KM; Neuroscience Discovery, Eli Lilly & Company, Indianapolis, IN 46285, USA., Mikkelsen JD; Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, 2100 Copenhagen, Denmark., Svensson KA; Neuroscience Discovery, Eli Lilly & Company, Indianapolis, IN 46285, USA.

Publikováno v: Neuroscience journal [Neurosci J] 2013; Vol. 2013, pp. 736439. Date of Electronic Publication: 2013 Nov 19.

Zobrazit plný text záznamu

Akademický článek

N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes.

Autor: Fell MJ; Neuroscience Discovery Research, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, DC0510, Indianapolis, IN 46285, USA. fell_matthew@lilly.com, Witkin JM, Falcone JF, Katner JS, Perry KW, Hart J, Rorick-Kehn L, Overshiner CD, Rasmussen K, Chaney SF, Benvenga MJ, Li X, Marlow DL, Thompson LK, Luecke SK, Wafford KA, Seidel WF, Edgar DM, Quets AT, Felder CC, Wang X, Heinz BA, Nikolayev A, Kuo MS, Mayhugh D, Khilevich A, Zhang D, Ebert PJ, Eckstein JA, Ackermann BL, Swanson SP, Catlow JT, Dean RA, Jackson K, Tauscher-Wisniewski S, Marek GJ, Schkeryantz JM, Svensson KA

Publikováno v: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2011 Jan; Vol. 336 (1), pp. 165-77. Date of Electronic Publication: 2010 Oct 14.

Zobrazit plný text záznamu

Akademický článek

The 5-hydroxytryptamine2A receptor antagonist R-(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl-4-piperidinemethanol (M100907) attenuates impulsivity after both drug-induced disruption (dizocilpine) and enhancement (antidepressant drugs) of differential-reinforcement-of-low-rate 72-s behavior in the rat.

Autor: Ardayfio PA; Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, USA., Benvenga MJ, Chaney SF, Love PL, Catlow J, Swanson SP, Marek GJ

Publikováno v: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2008 Dec; Vol. 327 (3), pp. 891-7. Date of Electronic Publication: 2008 Sep 04.

Zobrazit plný text záznamu

Akademický článek

Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine.

Autor: Rasmussen K; Lilly Research Laboratories, Eli Lilly and Co., Lilly Corporate Center, Indianapolis, IN 46285, USA. rasmussen_kurt@lilly.com, Benvenga MJ, Bymaster FP, Calligaro DO, Cohen IR, Falcone JF, Hemrick-Luecke SK, Martin FM, Moore NA, Nisenbaum LK, Schaus JM, Sundquist SJ, Tupper DE, Wiernicki TR, Nelson DL

Publikováno v: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2005 Dec; Vol. 315 (3), pp. 1265-77. Date of Electronic Publication: 2005 Sep 01.

Zobrazit plný text záznamu

Akademický článek

The selective norepinephrine reuptake inhibitor, LY368975, reduces food consumption in animal models of feeding.

Autor: Gehlert DR; Neuroscience and Endocrine Research, Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA., Dreshfield L, Tinsley F, Benvenga MJ, Gleason S, Fuller RW, Wong DT, Hemrick-Luecke SK

Publikováno v: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 1998 Oct; Vol. 287 (1), pp. 122-7.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání